Steelhead Capital Management LLC

Search
⚲

Steelhead Capital Management LLC ✚
CRD #	173440
SEC #	801-117461
CIK #	0001813887
AUM	202.5 M (2026-03-30)
Employees	6 (67% Investors, 0% Brokers)
Phone	817-984-9197
Address	1751 River Run Fort Worth, TX 76107
Source	[IAPD] [EDGAR] [Website] [LinkedIn]

Total AUM ($M) Copy

Sector	Form 13F Holdings	Value ($M)
	Actuate Therapeutics Inc	27.5
	Rexahn Pharmaceuticals Inc	16.8
	Cognition Therapeutics Inc	4.6
	Aileron Therapeutics Inc	2.6
	Lantern Pharma Inc	1.2
	In8Bio Inc	0.2

Holdings by Sector ($M)

Type	Form D Funds	Date	Sold	AUM
VC	BIOS Actuate Co-Invest III LP	[2023-03-30]	3.2 M	3.6 M
	Filed 2022-12-06 (D) · Exemption 506(b) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Sirpant Co-Invest I LP	[2022-03-29]	5.5 M	5.4 M
	Offered $10,000,000 · Filed 2021-11-05 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $10,000 · Remaining $4,530,000 · Duration One year or less · Commission $15,900 · Revenue Decline to Disclose
VC	BIOS Sirpant Co-Invest I QP LP	[2022-03-29]	5.5 M	5.4 M
	Offered $10,000,000 · Filed 2021-11-05 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000 · Remaining $4,533,700 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Actuate Co-Invest II LP	[2021-03-31]		12.8 M
	Offered $30,000,000 · Filed 2020-09-25 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $30,000,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS ONL Co-Invest I LP	[2021-03-31]		12.6 M
	Offered $10,000,000 · Filed 2020-09-25 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $10,000,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Fund III LP	[2020-03-25]	48.0 M	12.0 M
	Offered $100,000,000 · Filed 2020-07-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $52,032,000 · Duration More than one year · Revenue Decline to Disclose
VC	BIOS Fund III NT LP	[2020-03-25]	3.9 M	13.5 M
	Offered $100,000,000 · Filed 2020-07-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $96,133,000 · Duration More than one year · Revenue Decline to Disclose
VC	BIOS Fund III QP LP	[2020-03-25]	48.0 M	81.8 M
	Offered $100,000,000 · Filed 2020-07-22 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $52,032,000 · Duration More than one year · Revenue Decline to Disclose
VC	BIOS Actuate Co-Invest I LP	[2019-09-09]		1.8 M
	Offered $5,000,000 · Filed 2019-03-26 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $5,000,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Azitra Co-Invest I LP	[2019-09-09]	0.4 M	0.4 M
	Offered $3,000,000 · Filed 2019-03-11 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $2,562,500 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Immusoft Co-Invest I LP	[2019-09-09]	0.8 M	0.1 M
	Offered $3,000,000 · Filed 2019-01-15 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $2,250,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS LTI Co-Invest III LP	[2019-09-09]	12.2 M	3.8 M
	Offered $30,000,000 · Filed 2019-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $17,785,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS LTI Co-Invest III QP LP	[2019-09-09]	15.1 M	3.9 M
	Offered $30,000,000 · Filed 2019-05-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $14,885,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Fund II NT LP	[2018-09-19]	5.0 M	3.0 M
	Offered $50,000,000 · Filed 2018-10-01 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $44,980,000 · Duration More than one year · Revenue Decline to Disclose
VC	BIOS Fund II LP	[2018-03-30]	11.5 M	6.8 M
	Offered $50,000,000 · Filed 2018-10-01 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $38,485,000 · Duration More than one year · Revenue Decline to Disclose
VC	BIOS Fund II QP LP	[2018-03-30]	37.0 M	22.4 M
	Offered $50,000,000 · Filed 2018-10-01 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $13,027,000 · Duration More than one year · Revenue Decline to Disclose
VC	BIOS Fund I LP	[2018-03-30]	14.4 M	6.2 M
	Offered $14,430,412 · Filed 2017-03-24 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $5,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Fund I QP LP	[2018-03-30]	8.4 M	3.6 M
	Offered $8,390,945 · Filed 2017-03-24 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $20,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS OMI SPV I LP	[2017-03-28]	0.8 M	1.5 M
	Offered $1,545,000 · Filed 2016-12-09 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $5,000 · Remaining $705,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Memory SPV II LP	[2016-03-30]	0.8 M	0.5 M
	Offered $1,000,000 · Filed 2016-03-29 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $3,414 · Remaining $187,216 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS LTI SPV II LP	[2016-02-16]	0.5 M	1.4 M
	Offered $6,000,000 · Filed 2015-12-15 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $15,000 · Remaining $5,505,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Memory SPV I LP	[2015-10-26]	2.1 M	1.9 M
	Offered $4,500,000 · Filed 2015-06-05 (D) · Exemption 506(b) · Minimum $25,000 · Remaining $2,435,000 · Duration One year or less · Revenue Decline to Disclose
VC	BIOS Vision SPV II LP	[2015-10-26]	1.0 M	0.9 M
	Offered $1,449,071 · Filed 2015-08-12 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining $493,228 · Duration One year or less · Revenue Decline to Disclose
VC	SCM-Bios Lung Therapeutics SPV LP	[2015-10-26]		8.9 M
	Offered $2,000,000 · Filed 2014-08-21 (D) · Exemption 506(b) · Minimum $5,000 · Remaining $2,000,000 · Duration One year or less · Revenue No Revenues
VC	SCM Kutoa SPV I LP	[2015-10-26]	0.1 M	0.1 M
	Filed 2015-05-18 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $25,000 · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose
VC	SCM Vision LP	[2015-10-26]	0.5 M	0.8 M
	Offered $515,000 · Filed 2013-11-27 (D) · Exemption 506(b) · Minimum $5,000 · Duration One year or less · Commission $15,000 · Revenue No Revenues

AUM Breakdown	Accounts	AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals)	0	0.0
(b) Individuals (high net worth individuals)	0	0.0
(c) Banking or thrift institutions	0	0.0
(d) Investment companies	0	0.0
(e) Business development companies	0	0.0
(f) Pooled investment vehicles	20	202.5
(g) Pension and profit sharing plans	0	0.0
(h) Charitable organizations	0	0.0
(i) State or municipal government entities	0	0.0
(j) Other investment advisers	0	0.0
(k) Insurance companies	0	0.0
(l) Sovereign wealth funds and foreign official institutions	0	0.0
(m) Corporations or other businesses not listed above	0	0.0
(n) Other	0	0.0
Total	20	202.5
By Discretionary
Discretionary	20	202.5
Non-Discretionary	0	0.0
Total	20	202.5
By Non-United States Persons
Non-United States Persons		0.0
United States Persons		202.5
Total	20	202.5

Form D Directors	Role	# Filings	# Firms
Aaron Fletcher	Director, Executive Officer, Promoter	64	3
Leslie Kreis Jr	Director, Executive Officer, Promoter	42	3
Cavu Advisors	Director, Promoter	30	3
Cavu Management	Director, Promoter	30	3
Steelhead Capital Management	Director, Promoter	30	3
Bios Capital Management	Director, Promoter	29	3
Bios Advisors GP	Director, Promoter	29	3
Bios Capital Management LP	Promoter	8	3
Bios Advisors GP LLC	Director	4	3
Bios Equity Partners III	Director	12	2
View All

EDGAR Form	CIK	2011 - 2026
13F-NT	[0001813887]

Firm Profile (Form ADV)
Serves	Institutional

Comparable Firms	State	AUM
White Rock Oil & Gas Holdings LLC ✚	TX	205.1 M
Extant Capital LLC ✚	NY	204.3 M
Rayliant Investment Research ✚	CA	203.5 M
Harmont Fixed Income LLC ✚		202.8 M
Level One Global Advisors LLC ✚	FL	201.5 M
AI Alpha LLC ✚	MI	200.0 M
Gladowsky Capital Management Corp ✚	NY	197.8 M
Calvert Impact Advisory Services LLC ✚	MD	197.8 M
Reciprocal Venture Management LLC ✚	NY	196.9 M
Frugal Financial Retirement Plan Services LLC ✚	AL	194.9 M

Steelhead Capital Management LLC

Assets, Funds, Holdings